Compare ARK Next Generation Internet ETF (ARKW) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs BioNTech SE - ADR — how do they compare? ARK Next Generation Internet ETF trades at $149.98, while BioNTech SE - ADR trades at $92.99 (market cap $23.31B). The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ARKW | BNTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $119.34 |
52-Week Low | $114.45 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $150.88, up 0.87% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF focuses on next-generation internet companies, though key financial ratios are not disclosed in the provided data. Recent news highlights long-term growth potential in AI and cloud infrastructure, balanced by near-term capital spending headwinds.
The outlook is mixed, with strong technical momentum but fundamental metrics unavailable for valuation. Risks include market skepticism on AI investments and sector volatility. Analyst sentiment is cautious, citing near-term challenges despite long-term positioning in transformative technologies.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
